Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.22, $0.03 better than the analyst estimate of $0.19. Revenue for the quarter came in at $54.1 million versus the consensus estimate of $51.16 million.

Reaffirmed fiscal 2017 guidance of per share diluted earnings between $0.64 and $0.69 on net revenues of $193 million to $199 million.

GUIDANCE:

Meridian Bioscience sees FY2017 EPS of $0.64-$0.69. Meridian Bioscience sees FY2017 revenue of $193-199 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.